# Presentation: 820879

- National Institutes of Health
- US Department of Health & Human Services

**National Center for Research Resources**

*A** c c e l e r a t i n g   a n d   e n h a n c i n g   r e s e a r c h   f r o m   b a s i c   d i s c o v e r y    t o   i m p r o v e d   p a t i e n t   c a r e*

**Biomedical Technology**
**	****	****	****Discovery to Practice**

- Douglas M. Sheeley, Sc.D.
- Division of Biomedical Technology, NCRR
- May 22, 2007

## Biomedical Technology Research Resources

- Purpose:
- Engines for translation of advances in physical sciences to biomedical research

- Direct Distribution
- Workshops
- Commercialization
- Partnerships with clinical researchers
- (often in conjunction with GCRCs)

- Modes of Translation:

## Biomedical Technology Research Resources

- Multidisciplinary & collaborative, a catalyst for integrating diverse research efforts
- Since 1962 – 188 Resource awards (50 current)
- Long history of applications to both discovery and clinical research
- Seminal contributions in
- 			computation		NMR					imaging			crystallography
- 			microscopy		mass spectrometry
- Lessons to be learned from this history that can inform our approach to current challenges and opportunities

## Lessons from the Instrumental Revolution in Chemistry

**“****Shifting and Rearranging: Physical Methods and the Transformation of Modern Chemistry” **
**by Carston Reinhardt, Science History Publications, 2006.**

- In the mid-20th century, physical methods fundamentally changed the field of chemistry.
- Instrumental methods:
-  Changed how chemists approached their work
-  Created new interdisciplinary fields
- Accepted because data made sense in the context of existing knowledge (chemistry, quantum mechanics)
- It was the transparency of the technology that allowed it to be trusted and quickly be considered essential.

## Moving from Discovery to Practice

- Raman Spectroscopy in the Operating Room
- Laser Biomedical Research Center, MIT
- Michael Feld, PI
- Image-Guided Diagnosis and Therapy for Prostate Cancer
- National Center for Image Guided Therapy
- Brigham and Women’s Hospital
- Ferenc Jolesz, PI
- Mass Spectrometry for both diagnosis and basic research into Congenital Disorders of Glycosylation
- Mass Spectrometry Resource for Biology and Medicine
- Boston University School of Medicine
- Catherine Costello, PI

## In Vivo Raman Spectroscopy

**During Partial Mastectomy Breast Surgery**

- Performed in collaboration with Dr. Joseph Crowe at Cleveland Clinic.
- Raman spectra taken from margins immediately after tissue excision.
- Demonstrates our ability to collect *in vivo* spectra and make accurate diagnoses based on these data.

**Laser Biomedical Research Center, MIT****Michael Feld, PI**

## Clinical Raman Instrument

## In Vivo Margin Assessment

**Sensitivity = 100%(1/1)        **
**Specificity = 100%(29/29)           **
**Total Efficiency = 93%(28/30)**

- Haka *et al.*, *Cancer Research*, **66**(6): 3317-3322 (2006)

**Notes:**
So having described the probes and instrumentation, let me briefly summarize some clinical results in breast and artery tissues. So, here are results from the in vivo clinical study of breast cancer that was done at the Cleveland Clinic Foundation, OH. Raman instrument was used in the operating room. Totally, we acquired data from 12 patients. Raman spectra were collected in 1 second, which was enough to have good signal quality. Spectra were fit using linear combination of the breast model spectra. We were able to identify correctly the only one malignant specimen, that was grossly invisible. Therefore, our technique could save this patient from undergoing second surgery.

## Closed-loop Guidance and Control for Prostate Intervention

**Closed-loop Guidance and Control for Prostate Intervention**

## In-bore Needle Placement

**In-bore Needle Placement**

## Clinical Presentation:

**Clinical Presentation:**
**Wide range of symptoms and severity**
**Neurological impairment**
**Multiple organ system involvement**
**Hypoglycemia**
**Protein-losing enteropathy**
**Often misdiagnosed**
**(e.g. inherited mitochondrial disorders or ataxic cerebral palsy)**

**The CDG Family Network: www.cdgs.com**

**Mass Spectrometry Resource for Biology and Medicine****Boston University School of Medicine****Catherine Costello, PI**

**Mass Spectrometry for Diagnosis and Research into **
**Congenital Disorders of Glycosylation**

## Diagnosing CDGs: Patterns of Protein Glycosylation

- Freeze, H. H. Glycobiology 2001 11:129R-143R; doi:10.1093/glycob/11.12.129R

**Diagnosing CDGs: Patterns of Protein Glycosylation**

**Isoelectric Focusing**

**Mass Spectrometry**

## Understanding CDGs: Structural Details

**Understanding CDGs: Structural Details**

## Identify novel biomarkers
Clinical validation
Develop clinical tests 

**Clinical validation**
**Develop clinical tests **

**Alliance of Glycobiologists for Detection of Cancer and Cancer Risk**

- Karl Krueger, Cancer Biomarkers Research Group
- Division of Cancer Prevention, NCI

- BTRR-developed Technologies Facilitate NIH Programs

**Built around NCRR Glycomics Centers & NIGMS Consortium for Functional Glycomics**
**Program would not have been possible without those investments**
**Direct translation of BTRR technologies to clinical applications**

## Biomedical Technology Research Resources

- The CTSA program is a networked, wide-ranging infrastructure that will facilitate a transformation of the way we do clinical and translational research.
- How can BTRRs advance the goals of the CTSA program?
- Become a part of the CTSA community: fully engage the process that is now getting underway, bringing experience and perspective of physical science
- Work to understand unmet technological needs
- Provide access to highly developed infrastructure
- Provide training for physician/scientists
- Partner with clinical researchers to bring relevant technologies forward and make them transparent, trusted tools in both research and health care delivery